Biocryst Pharmaceuticals (BCRX) Enterprise Value (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Enterprise Value came in at -$67.7 million in Q1 2026, up 64.42% YoY from -$41.2 million in Q1 2025, and up 63.47% on a QoQ basis from -$185.2 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Enterprise Value (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Enterprise Value data on file, last reported at -$67.7 million in Q1 2026.
- Quarterly Enterprise Value rose 64.42% year-over-year to -$67.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$67.7 million (up 64.42% YoY) and the FY2025 annual result came in at -$185.2 million, up 42.27% from the prior year.
- Enterprise Value advanced to -$67.7 million in Q1 2026, from -$185.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$67.7 million in Q1 2026 to a low of -$443.5 million in Q1 2022.
- A 5-year average of -$277.2 million and a median of -$248.3 million in 2023 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 76.16% in 2022, down 2439.62% in 2022.
- Tracing BCRX's Enterprise Value over 5 years: stood at -$121.0 million in 2022, then tumbled by 221.44% to -$389.0 million in 2023, then gained by 17.52% to -$320.8 million in 2024, then surged by 42.27% to -$185.2 million in 2025, then soared by 63.47% to -$67.7 million in 2026.
- The last three Enterprise Value figures came in at -$67.7 million (Q1 2026), -$185.2 million (Q4 2025), and -$212.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | -164.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -352.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -352.57 Mn |
| Mar 31, 2026 | -67.66 Mn |
| Dec 31, 2025 | -185.21 Mn |
| Sep 30, 2025 | -212.87 Mn |
| Jun 30, 2025 | -172.50 Mn |
| Mar 31, 2025 | -190.19 Mn |
| Dec 31, 2024 | -320.85 Mn |
| Sep 30, 2024 | -330.01 Mn |
| Jun 30, 2024 | -195.41 Mn |
| Mar 31, 2024 | -336.55 Mn |
| Dec 31, 2023 | -388.99 Mn |
| Sep 30, 2023 | -248.27 Mn |
| Jun 30, 2023 | -410.67 Mn |
| Mar 31, 2023 | -244.49 Mn |
| Dec 31, 2022 | -121.02 Mn |
| Sep 30, 2022 | -426.86 Mn |
| Jun 30, 2022 | -417.48 Mn |
| Mar 31, 2022 | -443.47 Mn |
| Dec 31, 2021 | -507.60 Mn |
| Sep 30, 2021 | -199.60 Mn |